# A Composite Is Only Its Components

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/a-composite-is-only-its-components

> A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.

## Key points

- 57% of the tirzepatide 15 mg group met ≥3 standard targets vs 34% on semaglutide.
- The semaglutide dose was 1 mg (the diabetes strength), not the 2.4 mg weight dose.
- The gap is carried by HbA1c and weight; weight most of all (OR 3.86 for >15%).
- LDL cholesterol does not appear among the significant results at all.
- Post hoc: the targets were applied to the data afterward.

A reanalysis of SURPASS-2 asked how many standard treatment targets (blood sugar, blood pressure, cholesterol and weight) each drug got patients to, and tirzepatide won at every dose.[1] Before that means anything, note what was compared: tirzepatide at up to 15 mg against **semaglutide at 1 mg**, the diabetes dose. Then look at which targets moved.

## The dose question first

> **SURPASS-2 ran tirzepatide across its full range and semaglutide at a single low dose.** Semaglutide 1 mg is the type 2 diabetes strength; 2.4 mg is the weight-management strength. So this compares one drug at 5, 10 and 15 mg with another at a fraction of what it can be given at.

That is not a scandal. SURPASS-2 was a diabetes trial, 1 mg was the licensed diabetes dose when it ran, and comparing against an approved comparator at an approved dose is legitimate design. What it means is narrower than the sentence people extract from it. “Tirzepatide gets more patients to target than semaglutide 1 mg in type 2 diabetes” is supported. “Tirzepatide beats semaglutide” is not the same claim.

The trial that does compare them at their weight-management doses is a different study, and its quality-of-life analysis is covered in [the mental health score that did not move](https://glpwatchdog.org/research/the-mental-health-score-that-did-not-move).

## What the analysis did

The authors took 1,879 participants from SURPASS-2 and scored each against four standard targets and four stricter ones, at 40 weeks.

*The two target sets applied.[1]*

| Measure | Standard | Intensive |
| --- | --- | --- |
| HbA1c | < 7% | < 6.5% |
| Blood pressure | < 140/90 | < 130/80 |
| LDL cholesterol | < 1.8 mmol/l | < 1.4 mmol/l |
| Weight loss | > 10% | > 15% |

At baseline almost nobody was near all four. On the standard set, 19% met none and only 21% met two or more. On the intensive set, 58% met none and just 4% met two.

*Proportion meeting three or more targets at 40 weeks.[1]*

|   | Semaglutide 1 mg | Tirze 5 mg | Tirze 10 mg | Tirze 15 mg |
| --- | --- | --- | --- | --- |
| Standard targets | 34% | 42% | 53% | 57% |
| Intensive targets | 8% | 15% | 20% | 29% |

## Which components carried it

“Three of four targets” sounds like all-round metabolic control. The odds ratios show where the difference actually came from.

*Odds of reaching each individual target, tirzepatide against semaglutide 1 mg.[1]*

| Target | Odds ratio (95% CI) |
| --- | --- |
| HbA1c < 7% | 1.50 (1.12–2.00) |
| HbA1c < 6.5% | 1.88 (1.49–2.36) |
| Weight loss > 10% | 2.72 (2.14–3.47) |
| Weight loss > 15% | **3.86 (2.69–5.55)** |
| Blood pressure, intensive | 1.45 (1.17–1.81) |
| **LDL cholesterol** | **not among the significant results** |

Blood sugar and weight do the work, and weight does most of it, with nearly four times the odds of losing more than 15%. Blood pressure contributes only at the stricter threshold. LDL cholesterol does not appear at all.

> A composite counts its components equally. A drug does not affect them equally.

> **That is the general trap with any “met N of M goals” measure.** It reads as breadth, as being better across the board, when it can be produced entirely by being much better at two things and no different at the others. Whenever you meet a composite score, the useful question is which components moved, and the answer is often that one of them moved a great deal and carried the rest.

## What is useful here

Setting the framing aside, the underlying observation matters clinically. Most people with type 2 diabetes are not near their targets (in this trial, only 21% met two or more of the four at baseline), and getting to several at once has historically meant stacking several drugs, each with its own side effects and its own adherence cost.

A single agent moving two of the four substantially is a real simplification, and 57% reaching three or more standard targets is a large number in this population by any historical comparison. Put plainly, this drug is very good at two of these four things, and that turns out to be enough to move a composite a long way.

One structural note: the targets were applied to the trial data afterward rather than being its endpoints. That is standard and reasonable for this kind of question, and it is still a post hoc analysis.

## Frequently asked questions

### Does tirzepatide get more people to treatment targets than semaglutide?

Yes, in this reanalysis of SURPASS-2. In the 15 mg group, 57% met three or more standard targets against 34% on semaglutide. But the semaglutide dose was 1 mg, the diabetes strength, not the 2.4 mg used for weight management.

### Why does the dose matter?

Because it makes the comparison narrower than the headline. Tirzepatide was tested across its full range and semaglutide at a fraction of its own. The supported claim is about tirzepatide against semaglutide 1 mg in type 2 diabetes, not about the two drugs generally.

### Which targets did tirzepatide improve?

Blood sugar and weight, with weight carrying most of it (nearly four times the odds of losing over 15%). Blood pressure contributed only at the stricter threshold, and LDL cholesterol did not appear among the significant results.

### What is wrong with a 'met 3 of 4 goals' measure?

Nothing, as long as you look at the components. It reads as across-the-board improvement but can be produced entirely by a large effect on two goals and no effect on the others, because a composite weights its parts equally when a drug does not.

### Was this a prespecified analysis?

No. The targets were applied to SURPASS-2 data after the fact, which is a standard and reasonable approach to this question and still a post hoc analysis.

## References

1. Neves JS, Leite AR, Vale C, et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia. 2026. PMID: 41419618. https://pubmed.ncbi.nlm.nih.gov/41419618/

---

Cite as: GLP Watchdog, Nora Bissett, "A Composite Is Only Its Components", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/a-composite-is-only-its-components

Canonical HTML page: https://glpwatchdog.org/research/a-composite-is-only-its-components

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
